Meyer P R, Matsuura S E, Mian A M, So A G, Scott W A
Department of Biochemistry and Molecular Biology, University of Miami School of Medicine, Florida 33101, USA.
Mol Cell. 1999 Jul;4(1):35-43. doi: 10.1016/s1097-2765(00)80185-9.
Mutations in HIV-1 reverse transcriptase (RT) give rise to 3'-azido-3'-deoxythymidine (AZT) resistance by a mechanism that has not been previously reproduced in vitro. We show that mutant RT has increased ability to remove AZTMP from blocked primers through a nucleotide-dependent reaction, producing dinucleoside polyphosphate and extendible primer. In the presence of physiological concentrations of ATP, mutant RT extended 12% to 15% of primers past multiple AZTMP termination sites versus less than 0.5% for wild type. Although mutant RT also unblocked ddAMP-terminated primers more efficiently than wild-type RT, the removal of ddAMP was effectively inhibited by the next complementary dNTP (IC50 approximately equal to 12 microM). In contrast, the removal of AZTMP was not inhibited by dNTPs except at nonphysiological concentrations (IC50 > 200 microM).
HIV-1逆转录酶(RT)中的突变通过一种此前尚未在体外重现的机制导致对3'-叠氮基-3'-脱氧胸苷(AZT)产生耐药性。我们发现,突变型RT通过一种依赖核苷酸的反应,从受阻引物上移除AZTMP的能力增强,产生二核苷多磷酸和可延伸的引物。在生理浓度的ATP存在下,突变型RT能使12%至15%的引物越过多个AZTMP终止位点进行延伸,而野生型则低于0.5%。虽然突变型RT也比野生型RT更有效地解开ddAMP终止的引物,但ddAMP的移除会被下一个互补的dNTP有效抑制(IC50约等于12 microM)。相比之下,除了在非生理浓度下(IC50 > 200 microM),dNTPs不会抑制AZTMP的移除。